The firm saw decreases in its core diagnostics business that were offset in part by revenues from newly-acquired Magellan Diagnostics.
The test is an improved version of one that was approved three years ago, and runs on the firm's illumigene molecular diagnostics platform.
The life science and diagnostics company's revenues were short of analyst expectations, though its earnings per share were in line with estimates.
The company's net earnings rose, and it reaffirmed its guidance of $195 million to $200 million in revenues for full year 2016.
The LAMP-based test is faster and more sensitive, allowing faster treatment and more accurate diagnosis for malaria patients.
There were more winners than losers in the 2015 GWDN Index, but some lost big.
The company's direct-from-blood test detects low levels of plasmodium parasitemia and runs on Meridian's Illumigene isothermal molecular diagnostic platform.
Oasis, based in Vancouver, Washington, develops, manufactures, and sells pre-analytic tools for collecting, preserving, and transporting saliva and other oral fluids.
The Cincinnati, Ohio-based molecular diagnostics manufacturer reaffirmed fiscal 2016 guidance and declared a cash dividend.
A letter criticizing actions by the US government and research institutions toward Chinese and Chinese-American scientists has garnered more than a hundred signatories.
NPR reports that researchers in New York are investigating whether it is possible to edit the genomes of human sperm.
In an opinion piece at the Nation, Sarah Lawrence College's Laura Hercher argues that everyone should be able to access prenatal genetic testing.
In Nature this week: ancient DNA uncovers presence of Mediterranean migrants at a Himalayan lake, and more.